AGENDA

Uniform Formulary Beneficiary Advisory Panel (UF BAP)
For the August 2026 Department of War Pharmacy and Therapeutics Committee Meeting
September 23, 2026 at 10:00 AM Eastern Daylight Time

The UF BAP meeting occurring on September 23, 2026, will include information presented at the DoW Pharmacy and Therapeutics (P&T) Committee meetings held from August 4-5, 2026.

Information from the August 2026 DoW P&T Meeting

- **General session starts at 10:00 AM Eastern Daylight Time**
- **Roll Call**
- **Therapeutic Class Reviews**

  Members of the Defense Health Agency (DHA) Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effectiveness analyses along with the DoW P&T Committee recommendations for the Uniform Formulary (UF) and any recommended complete exclusion candidates.

  The DoW P&T Committee made recommendations for the following drugs/drug classes during the August 2026 meeting.

- **Drug Class Reviews**
  - *Oncological Agents: B-Raf proto-oncogene, serine/threonine kinase (BRAF) Mitogen-Activated Extracellular Signal-Regulated Kinase (MEK) Inhibitors Subclass*
  - *Attention Deficit Hyperactivity Disorder (ADHD): Stimulants Subclass*
- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
  - *anifrolimab-fnia injection (Saphnelo) – Immunosuppressive for Systemic Lupus Erythematosus (SLE)*
  - *atomoxetine 4 mg/mL oral solution (Atoncy) – ADHD Agents: Non Stimulants*
  - *baxdrostat (Baxfendy) – Diuretics*
  - *bimatoprost 0.01% ophthalmic gel (Zolymbus) – Glaucoma Drugs*
  - *bulevirtide-gmod injection (Hepcludex) – Hepatitis D Agents*
  - *doravirine/islatravir (Idvynso) – Antiretrovirals for Human Immunodeficiency Virus*

- *duloxetine 80-, 90-, 120 mg delayed release (DR) capsules (no brand name) – Antidepressants and Non-Opioid Pain Syndrome*
- *ensitrelvir fumarate (Xocova) – FDA-Approved Antivirals for COVID Therapeutics*
- *filgrastim-laha injection (Filkri) – White Blood Cell Stimulants biosimilar for Neupogen*
- *finafloxacin 0.3% otic suspension (Xtoro) – Antibiotics for acute otitis externa*
- *folic acid 0.2 mg/mL oral solution (Quiofic and authorized generic) – Vitamins*
- *linerixibat (Lynavoy) – Gastro-Intestinal (GI)-2 Agent for pruritus from primary biliary cholangitis*
- *milsaperidone (Bysanti) – Atypical Antipsychotic Agents*
- *relacorilant (Lifyorli) – Oncological Agents for Ovarian Cancer*
- *telmisartan/amlodipine/indapamide (Widaplik) – Renin-Angiotensin Antihypertensives (RAAs)*
- *tradipitant (Nereus) – Antiemetic-Antivertigo Agents*
- *vepdegestrant (Veppanu) -Breast Cancer Agents*

➢ **Utilization Management Issues**

- **PA Criteria—Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**
  - *Antidepressants and Non-Opioid Pain Syndrome Agents: Gamma-aminobutyric Acid Analogs—gabapentin 200-, 300-, 400 mg capsules (Relgaabi)*
  - *Antianxiety Agents—buspirone 2.5 mg and 12.5 mg tablets (no brand name)*
- **PA Criteria—New Manual PA Criteria**
  - *Antibiotics: Tetracyclines—omadacycline (Nuzyra)*
- **PA Criteria—Updated PA Criteria for New FDA-Approved Indications**
  - *Antidepressants and Non-Opioid Pain Syndrome Agents: Gamma-aminobutyric Acid Analogs—dextromethorphan/bupropion (Auvelity)*
  - *Antihemophilic Agents: Non-Factor Agents—marstacimab-hncq (Hympavzi)*
  - *Antilipidemic-2 Agents—olezarsen (Tryngolza)*
  - *Atopy: Interleukin (IL)-13, IL-31 Inhibitors—dupilumab (Dupixent)*

- *Breast Cancer Agents: PIK3CA—capivasertib (Truqap)*
- *Metabolic Agents Miscellaneous—setmelanotide (Imcivree)*
- *Nephrology Agents Miscellaneous—sparsentan (Filspari)*
- *Neurologic Agents Miscellaneous—efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)*
- *Pain Agents: Topical Pain—diclofenac epolamine 1.3% patch (Licart)*
- *Targeted Immunomodulatory Biologics (TIBs): IL 17 inhibitors—secukinumab (Cosentyx)*
- *(TIBs): IL 23 inhibitors—risankizumab (Skyrizi)*
- *(TIBs): IL 23 inhibitors—ustekinumab products (Starjemza, Imuldosa, , Pyzchiva, Selarsdi, Stelara, unbranded Stelara, unbranded Otulfi, Steqeyma, Wezlana, Yesintek)*

- **PA Criteria—Updated and New PA Criteria for Reasons Other Than New Indications**
  - *Antiemetic Antivertigo Agents—meclizine 25 mg chewable tablets (Antivert)*
  - *Antilipidemic-2 Agents—plozasiran (Redemplo)*
  - *Antipsychotic Agents: Atypical—iloperidone (Fanapt)*
  - *Atopy: IL-13, IL-31 Agents—nemolizumab (Nemluvio)*
  - *Breast Cancer Agents: Polyadenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors—niraparib (Zejula)*
  - *GI-2 Agents: Chronic Idiopathic Constipation (CIC) and Constipation-Predominant Irritable Bowel Syndrome (IBS-C)*
    - *plecanatide (Trulance)*
    - *prucalopride (Motegrity)*
    - *tenapanor (Ibsrela)*
  - *GI-2 Agents: Opioid Induced Constipation (OIC)*
    - *methylnaltrexone (Relistor)*
    - *naldemedine (Symproic)*
    - *naloxegol (Movantik)*
  - *Glaucoma Drugs—latanoprost 0.005% ophthalmic solution (Iyuzeh)*
  - *Hematological Agents—ropeginterferon alfa-2b-njft (Besremi)*
  - *Pulmonary Arterial Hypertension (PAH)—sotatercept-csrk (Winrevair)*
  - *Oncological Agents: Multiple Myeloma—selinexor (Xpovio*

- *RAAs—aprocitentan (Tryvio)*

- **Brand Over Generic Authorization and Tier 1 Copay**
  - *Additions*
    - *Leukemia and Lymphoma Agents: Breakpoint cluster (BCR)-Ableson (ABL) Tyrosine Kinase Inhibitors (TKIs)—bosutinib (Bosulif) tablets*
    - *Diabetes Non-Insulin: Dipeptidyl Peptidase 4 (DPP-4) inhibitors—sitagliptin (Januvia) tablets*
    - *TIBs: Miscellaneous—tofacitinib (Xeljanz) IR and ER tablets*
  - *Removals*
    - *Leukemia and Lymphoma Agents: BCR-ABL TKIs—nilotinib (Tasigna)*

- **Over-The-Counter (OTC) Formulary Additions**
  - *acetaminophen 325 mg tablets and oral suspension*
  - *aspirin 81 mg*

- **Drugs Designated with Complete Exclusion Status: Annual Review and Formulary Recommendation**
  - *Antihypertensive Agents: clonidine hydrochloride (HCl) 0.02 mg/mL oral solution (Javadin)*

- **Panel Discussions**

  The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoW P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.

- **Adjournment**